Saturday - December 13, 2025
Triplet Therapy Shows Promise for BPDCN, a rare blood cancer, in Dana-Farber Study
December 07, 2025
BOSTON, Massachusetts, Dec. 7 [Category: BizHospital] -- The Dana-Farber Cancer Institute issued the following news release:

* * *

Triplet Therapy Shows Promise for BPDCN, a rare blood cancer, in Dana-Farber Study

*

RESEARCH SUMMARY

Study Title: Tagraxofusp, azacitidine, and venetoclax (TAG-AZA-VEN) triplet therapy shows efficacy, tolerability, and transplant potential in patients with blastic plasmacytoid dendritic cell neoplasm . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products